Search
Q32 Bio Inc
QTTBAdd to Watchlist
13.090USD
+0.490+3.89%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
191.50MMarket Cap
4.69P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.89%
5 Days
-0.61%
1 Month
-6.50%
6 Months
+280.52%
Year to Date
+294.28%
1 Year
+809.03%
Key Figures
12.680Open
13.300High
162.68KVolume
4.69P/E TTM
LossP/E Dynamic
--Dividend TTM
1.11%Turnover Ratio
12.600Prev. Close
12.540Low
1.67MTurnover
LossP/E Static
4.13P/B
0.00%Div Yield TTM
46.58%ROA
8.04552wk High
0.65Volume Ratio
-47.73MNet Profit
14.63MShares
2.7889EPS TTM
-0.13Beta
157.18%ROE
1.34552wk Low
6.03%Amplitude
100.00%Gross Margin
191.50MMarket Cap
-1.03Reward/Risk
9.76%Risk Rate
TradingKey Stock Score of Q32 Bio Inc
Currency: USD Updated: 2026-07-02Key Insights
Q32 Bio Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 85 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.25.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Q32 Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Q32 Bio Inc Highlights
StrengthsRisks
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 4548.53% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 53.74M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 4.69, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 9.99M shares, decreasing 17.01% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 2.42K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.43.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
14.250
Target Price
+13.10%
Upside Space
Q32 Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Q32 Bio Inc Info
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Ticker SymbolQTTB
CompanyQ32 Bio Inc
CEOMorrison (Jodie Pope)
Websitehttps://www.q32bio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Q32 Bio Inc (QTTB)?
The current price of Q32 Bio Inc (QTTB) is 13.09.
What is the symbol of Q32 Bio Inc?
The ticker symbol of Q32 Bio Inc is QTTB.
What is the 52-week high of Q32 Bio Inc?
The 52-week high of Q32 Bio Inc is 8.04.
What is the 52-week low of Q32 Bio Inc?
The 52-week low of Q32 Bio Inc is 1.34.
What is the market capitalization of Q32 Bio Inc?
The market capitalization of Q32 Bio Inc is 191.50M.
Is Q32 Bio Inc (QTTB) currently rated as Buy, Hold, or Sell?
According to analysts, Q32 Bio Inc (QTTB) has an overall rating of Buy, with a price target of 14.25.
What is the Earnings Per Share (EPS TTM) of Q32 Bio Inc (QTTB)?
The Earnings Per Share (EPS TTM) of Q32 Bio Inc (QTTB) is 2.42.